"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

As generative AI continues to reshape the legal and corporate landscapes, actionable steps should now be at the forefront of crisis communication plans to help firms combat the rapid spread of ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

If any pharmaceutical producer is going to exploit the full potential of such medications, it's the well-capitalized Eli Lilly. I would even consider it to be a leading healthcare stock ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company (NYSE ... However, InvestingPro's Fair Value analysis suggests the stock may be trading above its intrinsic value, warranting careful consideration by investors.